On January 18 (local time), DongKook Pharmaceutical's herbal gum medicine Insadol was approved by Swissmedic as an over-the-counter drug, enabling full-scale export to Europe.
The license recognizes the efficacy of Insadol in treating gum diseases where dental treatment alone is insufficient. In particular, it is significant that the regulatory agency of a representative pharmaceutical developed country has recognized its effectiveness in early periodontal disease including early gum inflammation.
Dongkuk Pharmaceutical, which used to import finished products from Europe with more advanced pharmaceutical technology than Korea 50 years ago, now produces excellent products and exports them to Switzerland by not only synthesizing its own raw materials but also conducting clinical research and changing the formulation for ease of use.
"Switzerland is not only a pharmaceutical powerhouse, but also a developed country with world-class dental schools and leading dental-related companies," said Dr. Kim Nam-yoon, vice president of the Korean Society of Periodontology. "This approval means that the efficacy of the gum used in Korea has been recognized in a dental powerhouse."
"Starting with the export to Switzerland based on the approval of the Swiss Medicines Agency, which is highly recognized worldwide, we plan to further accelerate the development of Europe and overseas markets," said Song Jun-ho, CEO of Dongkuk Pharmaceutical. "We will conduct active marketing activities such as academic symposiums to expand overseas markets including Switzerland."
